Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our financial condition and results of operations in conjunction with our condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025. In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled "Risk Factors" under Part II, Item 1A below. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements related to our expectations regarding our future results of operations and financial position, the use and adequacy of our existing cash to achieve our business goals, business strategy, market size for our product candidates, potential future milestone and royalty payments, potential growth opportunities, nonclinical and clinical development activities, efficacy and safety profile of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of nonclinical studies and clinical trials, collaboration with third parties, the impact of health pandemics, tariffs, regional geopolitical conflicts, changes in interest rates, inflation, potential uncertainty with respect to the debt ceiling and government shutdowns, on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, are forward-looking statements. The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "predict," "target," "intend," "could," "would," "should," "project," "plan," "expect," and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete; and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Overview

We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF®, and our site-specific conjugation platform, XpressCF+®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual-payload ADCs, or dpADCs. Our molecules are directed primarily against clinically validated targets where the current standard of care is suboptimal. We believe that our platform allows us to accelerate the discovery and development of potential first-in-class and/or best-in-class molecules by enabling the rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need.

Our highest priority wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor, or TF, which we are developing for the treatment of solid tumors. We believe STRO-004 has the potential to be a best-in-class ADC targeting TF. In preclinical studies, STRO-004 has demonstrated potent antitumor activity and the potential for a differentiated safety profile. We submitted an IND and received IND clearance for STRO-004 in October 2025, and initiated a Phase 1 trial in November 2025.

The Phase 1 open-label, multicenter trial of STRO-004 is designed to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in patients with advanced TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, urothelial cancer and gastric/esophageal cancer. The dose-escalation phase includes multiple cohorts, supported by strong tolerability in non-human primates at up to 50 mg/kg. In August 2026, we reported encouraging early clinical activity including confirmed and unconfirmed partial responses across three tumor types at 3 and 4 mg/kg dose levels, along with favorable safety and pharmacokinetics (PK) observed in the ongoing Phase 1 trial.

Dose optimization continues in backfill cohorts of selected indications. We expect to provide the next update on STRO-004 development in the first half of 2027. Further, we expect to initiate expansion cohorts in one or more of the indications of interest in the first half of 2027.

Our next wholly-owned clinical asset is STRO-006. STRO-006 is an ADC targeting Integrin β6, or ITGB6. We believe STRO-006 has the potential to be a best-in-class ADC targeting ITGB6 based on preclinical studies that have

demonstrated potent antitumor activity and the potential for a differentiated safety profile. We announced the first patient dosed in a Phase 1 clinical trial in connection with STRO-006 in October 2026.

The Phase 1 open-label, multicenter trial of STRO-006 is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of STRO-006 in patients with refractory solid tumors that are recurrent or metastatic, including head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal/gastric cancer, colorectal cancer, endometrial carcinoma, urothelial carcinoma, and breast cancer. The dose-escalation phase includes multiple cohorts with ascending dose levels, supported by evidence of strong tolerability in non-human primate studies at up to 30 mg/kg. We expect to provide an initial clinical update with STRO-006 in the second half of 2027.

Our lead preclinical asset is STRO-227. STRO-227 is our first wholly-owned dual-payload ADC, targeting Protein Tyrosine Kinase 7, or PTK7. This approach incorporates two distinct cytotoxic payloads, MMAE (DAR2) is designed to inhibit tubulin and exatecan (DAR8) is designed to inhibit topoisomerase, enabling complementary mechanisms of action within a single molecule. We have initiated certain chemistry, manufacturing and controls, or CMC, related activities for the PTK7-targeting dual-payload ADC and anticipate initiating a Phase 1 clinical trial with this program in early 2027.

Enabled through our proprietary XpressCF® and XpressCF+® platforms, we have entered into multitarget, product-focused collaborations with leading pharmaceutical and biotechnology companies in the field of oncology and we may enter into additional such collaborations in the future. We have an ongoing multitarget iADC collaboration with Astellas Pharma Inc. for the development of iADC targets. Clinical trials for the first iADC licensed pursuant to the Astellas Agreement were initiated in the first quarter of 2026 and clinical trials for the second iADC collaboration program were initiated in the third quarter of 2026. In addition, we may partner or out-license our wholly-owned preclinical or clinical development programs depending on resource and capital availability.

Our XpressCF® and XpressCF+® platforms have also supported Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease. The lead programs for Vaxcyte are VAX-31 and VAX-24, its 31-valent and 24-valent, respectively, pneumococcal conjugate vaccine candidates. Vaxcyte is responsible for performing all research and development activities and we provide technical support. In June 2023, we entered into a purchase and sale agreement, or the Purchase Agreement, with Blackstone, in which Blackstone acquired the right to receive our 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte products, including Vaxcyte's pneumococcal conjugate vaccine, or PCV, products, such as VAX-24 and VAX-31. Following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of an amendment to the licensing agreement, the revenue interest in the 4% royalty on potential future sales of Vaxcyte products other than Vaxcyte's PCV products reverted to us. Thus, we retain the right to receive a 4% royalty on sales of Vaxcyte's products other than PCV products. In November 2023, Vaxcyte exercised its option to access expanded rights to develop and manufacture cell-free extract for use in development and manufacture of its vaccine products, among certain other rights.

Since the commencement of our operations, we have devoted substantially all of our resources to performing research and development and manufacturing activities in support of our own product development efforts and those of our collaborators, raising capital to support and expand such activities and providing general and administrative support for these operations. We have funded our operations to date primarily from upfront, milestone and other payments under our collaboration agreements with BMS, Merck, Astellas, Vaxcyte, Ipsen, EMD Serono, BioNova, and Tasly, the issuance and sale of redeemable convertible preferred stock, our initial public offering, or IPO, follow-on public and other offerings of common stock, sales of our common stock through our At-the-Market Facility pursuant to our Open Market Sales AgreementSM dated April 2, 2021 with Jefferies LLC, which was terminated in March 2026, our At-the-Market Facility pursuant to our Sales Agreement dated March 23, 2026, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, debt financing, sale of our holdings of Vaxcyte common stock, and the royalty monetization agreement with Blackstone.

In March 2025, our Board of Directors approved a strategic portfolio review, or the March 2025 Restructuring Plan, with an associated planned reduction in our workforce, as a result of its review of current strategic priorities, resource allocation, and cost reduction intended to reduce operating costs, streamline operations and extend our cash runway. In connection with this March 2025 Restructuring Plan, we deprioritized further investment in our late-stage clinical development product candidate, luveltamab tazevibulin, which development has been terminated, and refocused our activities on our clinical and preclinical pipeline, including STRO-004, STRO-227, and STRO-006. In addition, in 2025, we made the strategic decision to cease operations at our San Carlos manufacturing facility and rely on an external manufacturing strategy, in which all elements of our product candidates and platform reagents are manufactured by qualified third-party contract manufacturing organizations, or CMOs. We have identified CMOs to serve as our strategic partners for the production of cell-free extract and custom reagents used in our cell-free production, and have completed technology transfers to these CMOs. Given the success of these technology transfers, we wound down our manufacturing activities in our San Carlos facility at the end of 2025 and completed the exit of the facility in 2026 upon expiration of our leases.

In September 2025, we announced a further reduction in our workforce of approximately one third of our remaining employees, or the September 2025 Restructuring Plan, and, together with the March 2025 Restructuring Plan, the Restructuring Plans, which was intended to further reduce operating costs, streamline operations, and extend our cash runway.

We do not have any products approved for commercial sale and have not generated any revenue from commercial product sales. We had a loss from operations of $81.5 million and a net loss of $108.5 million for the nine months ended September 30, 2026. We had a loss from operations of $120.3 million and a net loss of $144.3 million for the nine months ended September 30, 2025. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We cannot assure you that we will have net income or that we will generate positive cash flow from operating activities in the future. As of September 30, 2026, we had an accumulated deficit of $1,086.5 million. We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, access, marketing, manufacturing and distribution. In light of our current resources and the cost of development, we are continuing our process of evaluating our programs and spending. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials, our expenditures on other research and development and general and administrative activities, and the timing of achievement and receipt of upfront, milestone and other collaboration agreement payments.

Financial Operations Overview

Revenue

We do not have any products approved for commercial sale and have not generated any revenue from commercial product sales. Our total revenue to date has been generated principally from our collaboration and license agreements with Astellas, Vaxcyte, and other collaborators, and to a lesser extent, from manufacturing, supply and services and materials we provide to the above collaborators.

We derive revenue from collaboration arrangements, under which we may grant licenses to our collaboration partners to further develop and commercialize our proprietary product candidates. We may also perform research and development activities under the collaboration agreements. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial milestones and other contingent payments, and royalties based on net sales of approved products. Additionally, the collaborations may provide options for the customer to acquire from us materials and reagents, clinical product supply or additional research and development services under separate agreements. We assess which activities in the collaboration agreements are considered distinct performance obligations that should be accounted for separately. We develop assumptions that require judgment to determine whether the license to our intellectual property is distinct from the research and development services or participation in activities under the collaboration agreements.

At the inception of each agreement, we determine the arrangement transaction price, which includes variable consideration, based on the assessment of the probability of achievement of future milestones and contingent payments and other potential consideration. We recognize revenue over time by measuring our progress towards the complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the service promised to the customer.

For arrangements that include multiple performance obligations, we allocate the transaction price to the identified performance obligations based on the standalone selling price, or SSP, of each distinct performance obligation. In instances where SSP is not directly observable, we develop assumptions that require judgment to determine the SSP for each performance obligation identified in the contract. These key assumptions may include full-time equivalent, or FTE, personnel effort, estimated costs, discount rates and probabilities of clinical development and regulatory success.

Operating Expenses

Research and Development

Research and development expenses represent costs incurred in performing research, development and manufacturing activities in support of our own product development efforts and those of our collaborators, and include salaries, employee benefits, stock-based compensation, laboratory supplies, outsourced research and development expenses, professional services, and allocated facilities and IT-related costs. We expense both internal and external research and development costs as they are incurred. Nonrefundable advance payments for services that will be used or

rendered for future research and development activities are recorded as prepaid expenses and recognized as expenses as the related services are performed.

The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates.

The following table summarizes our research and development expenses incurred during the indicated periods. The internal costs include personnel, facility costs and research and scientific related activities associated with our pipeline. The external program costs reflect external costs attributable to our clinical development candidates and preclinical candidates selected for further development. Such expenses include third-party costs for preclinical and clinical studies and research, development and manufacturing services, and other consulting costs.

General and Administrative

Our general and administrative expenses consist primarily of personnel costs, expenses for outside professional services, including legal, human resources, audit, accounting and tax services and allocated facilities and IT-related costs. Personnel costs include salaries, employee benefits and stock-based compensation. We expect to incur expenses operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and listing standards applicable to companies listed on the Nasdaq Global Market, additional insurance expenses, investor relations activities and other administrative and professional services.

Restructuring and Related Costs

In March 2025, we announced the March 2025 Restructuring Plan resulting in the prioritization of our three wholly-owned preclinical programs in our next-generation ADC pipeline. We also announced that we were deprioritizing additional investment into development of luvelta across all indications and were reducing headcount by nearly 50 percent. In September 2025, we announced a further reduction in our workforce of approximately one third of our remaining employees. In connection with these events, we reported clinical trial expenses and other third-party costs for the deprioritization of the luvelta program in "Restructuring and Related Costs" in our interim condensed Statements of Operations.

Interest Income

Interest income consists primarily of interest earned on our invested funds.

Non-cash Interest Expense related to the Sale of Future Royalties

Non-cash interest expense related to the sale of future Vaxcyte royalties represents the imputed interest expense on our deferred royalty obligation related to the sale of future Vaxcyte royalties pursuant to the Purchase Agreement, using the effective interest method. As further described in the interim condensed financial statements in Note 8. Deferred Royalty Obligation related to the Sale of Future Royalties, in June 2023, we entered into the Purchase Agreement with Blackstone, pursuant to which we sold to Blackstone our 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte's PCV products, such as VAX-24 and VAX-31.

Non-cash interest expense will be recognized over the estimated life of the royalty term arrangement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement.

Interest and Other Income (Expense), Net

Interest expense primarily includes a financing component under the Astellas Agreement and recorded interest expense associated with the upfront payment. Interest and other income (expense), net also includes foreign currency transaction gains and losses.

Comparison of the Three Months Ended September 30, 2026 and 2025

*Percentage not meaningful

Revenue

We have recognized revenue as follows during the indicated periods:

Total revenue decreased by $0.6 million, or 6%, during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. This was primarily due to a $0.5 million decrease from Astellas, related to a $0.8 million net decrease in research and development services and materials supply, partially offset by a $0.1 million increase in ongoing performance on partially unsatisfied performance obligations under the Astellas Agreement, and a $0.2 million increase from the financing component under the Astellas Agreement. Revenue from ongoing performance obligations in the third quarter of 2026 included a $9.2 million positive cumulative catch-up adjustment related to the September milestone and a $5.7 million downward cumulative catch-up adjustment resulting from an increase in estimated total FTE effort required to complete the remaining research and development activities.

Research and Development Expense

Research and development expense decreased by $16.4 million, or 41%, during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The overall decrease was due primarily to decreases of $9.8 million in outside services, $3.7 million in personnel-related expenses, $2.6 million in allocated facilities and IT-related expenses, $0.9 million in laboratory supplies, and $0.4 million in equipment and office-related expenses, partially offset by a $1.2 million increase in preclinical research and clinical development expenses. Following the implementation of the March 2025 Restructuring Plan, we began reporting restructuring costs and other costs associated with the deprioritized luvelta program under "Restructuring and related costs" in our interim condensed financial statements.

General and Administrative Expense

General and administrative expense decreased by $1.2 million, or 14%, during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The overall decrease was due primarily to decreases of $0.7 million in outside services, $0.3 million in personnel-related expenses, $0.1 million in allocated facilities and IT-related expenses, and $0.1 million in equipment and office-related expenses.

Restructuring and Related Costs

The following table presents the components of restructuring and related costs from the Restructuring Plans, as further described and disclosed in Note 10 to our condensed financial statements:

We do not expect significant restructuring expenses in future periods for the deprioritization of the luvelta program and related costs. The ultimate amount of expense will be affected by the timing to complete our cost commitments to our third-party CROs and CMOs and the full wind-down of the clinical trials. We will revise our estimates for the costs to deprioritize these studies for the luvelta program as new information becomes available to us in future periods.

Interest Income

Interest income decreased by $0.5 million during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, due primarily to lower average investment balances and lower average rates of return in 2026.

Non-cash Interest Expense related to the Sale of Future Royalties

Non-cash interest expense increased by $0.5 million during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. Non-cash interest expense was recognized on our deferred royalty obligation related to the June 2023 sale of future Vaxcyte royalties pursuant to the Purchase Agreement, using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement.

Interest and Other Income (Expense), Net

Interest and other income (expense), net, increased by $0.1 million during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, primarily due to the financing component related to the Astellas Agreement.

Comparison of the Nine Months Ended September 30, 2026 and 2025

Revenue

We have recognized revenue as follows during the indicated periods:

Total revenue decreased by $57.4 million, or 63%, during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. This was primarily due to a $56.4 million decrease from Ipsen, which included the derecognition of $53.2 million in deferred revenue as a result of Ipsen's strategic decision not to advance the STRO-003 program under its partnership with us and a $3.2 million decrease in research and development services and manufacturing activities supporting clinical trial supply. Revenue decreased by $0.7 million from Astellas, due to decreases of $2.1 million related to ongoing performance on partially unsatisfied performance obligations and $0.4 million related to the financing component under the Astellas Agreement, partially offset by a $1.8 million increase in research and development services and materials supply. Revenue from ongoing performance obligations in 2026 included $18.3 million in positive cumulative catch-up adjustments related to milestones earned during the period and a $5.7 million downward cumulative catch-up adjustment resulting from an increase in estimated total FTE effort required to complete the remaining research and development activities. Revenue also decreased by $0.3 million from Vaxcyte, related to research and development services and materials supply, and $0.1 million from Tasly, related to materials supply.

Research and Development Expense

Research and development expense decreased by $38.0 million, or 29%, during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The overall decrease was due primarily to decreases of $17.5 million in personnel-related expenses, $10.6 million in outside services, $9.1 million in allocated facilities and IT-related expenses, $7.1 million in laboratory supplies, $0.9 million in equipment and office-related expenses, and $0.1 million in travel-related expenses, partially offset by increases of $6.9 million in technology transfer expenses primarily related to a negotiated resolution associated with a preexisting technology transfer cost-sharing arrangement, and $0.5 million in preclinical research and clinical development expenses. Following the implementation of the Restructuring Plans, we began reporting restructuring costs and other costs associated with the deprioritized luvelta program under "Restructuring and related costs" in our interim condensed financial statements.

General and Administrative Expense

General and administrative expense decreased by $9.4 million, or 29%, during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The overall decrease was due primarily to decreases of $5.8 million in personnel-related expenses, $2.8 million in outside services, $0.4 million in allocated facilities-related expenses, $0.2 million in travel-related expenses, and $0.2 million in equipment and office-related expenses. Some general and administrative expenses previously recorded under this category are now reported under "Restructuring and related costs" in our interim condensed financial statements following the implementation of our Restructuring Plans.

Restructuring and Related Costs

The following table presents the components of restructuring and related costs, as further described and disclosed in Note 10 to our condensed financial statements:

We do not expect significant restructuring expenses in future periods for the deprioritization of the luvelta program and related costs. The ultimate amount of expense will be affected by the timing to complete our cost commitments to our third-party CROs and CMOs and the full wind-down of the clinical trials. We will revise our estimates for the costs to deprioritize these studies for the luvelta program as new information becomes available to us in future periods.

Interest Income

Interest income decreased by $2.9 million during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, due primarily to lower average investment balances and lower average rates of return in 2026.

Non-cash Interest Expense related to the Sale of Future Royalties

Non-cash interest expense increased by $0.8 million during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. Non-cash interest expense was recognized on our deferred royalty obligation related to the June 2023 sale of future Vaxcyte royalties pursuant to the Purchase Agreement, using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of potential future royalty payments to be earned and received by Blackstone from Vaxcyte under the 2015 License Agreement.

Interest and Other Income (Expense), Net

Interest and other income (expense), net, decreased by $0.7 million during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, due to a $0.4 million decrease in interest expense related to the financing component of the Astellas Agreement and a $0.3 million decrease in foreign exchange losses.

Liquidity and Capital Resources

Sources of Liquidity

To date, we have incurred significant net losses, and negative cash flows from operations. Our operations have been funded primarily by payments received from our collaborators, and net proceeds from equity sales, debt, sale of shares of Vaxcyte common stock, and a royalty monetization. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $142.2 million, and an accumulated deficit of $1,086.5 million.

Contingent Payments from Astellas

In the first quarter of 2025, we earned a $7.5 million contingent payment from Astellas for its initiation of an IND-enabling toxicology study for the first program under our collaboration with Astellas. In the fourth quarter of 2025, we earned a $7.5 million contingent payment from Astellas for its initiation of an IND-enabling toxicology study for the second program under our collaboration with Astellas. In the first quarter of 2026, we earned a $10.0 million contingent payment from Astellas for its dosing of the first subject in a Phase 1 clinical trial in the territory for the first program under our collaboration with Astellas. In the third quarter of 2026, we earned a $10.0 million contingent payment from Astellas for its dosing of the first subject in a Phase 1 clinical trial in the territory for the second program under our collaboration with Astellas.

Underwritten Offering

On February 9, 2026, we entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the "Underwriters"), pursuant to which we agreed to issue and sell 7,868,383 shares of our common stock (the "Shares") to the Underwriters (the "February 2026 Offering"). The Shares were sold at an offering price of $13.98 per share. The gross proceeds from the February 2026 Offering were approximately $110.0 million, before deducting underwriting discounts and commissions and February 2026 Offering expenses.

Leases

In September 2020, we entered into a sublease agreement (the "Sublease") with Five Prime Therapeutics, Inc. (the "Sublessor") for approximately 115,466 square feet, in a building located in South San Francisco, California (the "Premises"). We use the Premises as our corporate headquarters and to conduct (or expand) research and development activities. We commenced making monthly payments for the first 85,755 square feet of the Premises, or Initial Premises, in July 2021, with occupancy of such space commencing in August 2021. We were provided early access to the Initial Premises in the fourth quarter of 2020 to conduct certain planning and tenant improvement work. The Sublease is subordinate to the lease agreement, effective December 12, 2016, between the Sublessor and HCP Oyster Point III LLC (the "Landlord"). We commenced using the remaining 29,711 square feet of the Premises (the "Expansion Premises") on July 1, 2023 under the Sublease. The Sublease for both the Initial Premises and Expansion Premises will expire on December 31, 2027. With a commencement date on the Initial Premises of July 1, 2021, and Expansion Premises of July 1, 2023, the aggregate estimated base rent payments due over the term of the Sublease are approximately $40.4 million, including the approximately $5.2 million in potential financial benefit to us of base rent abatement to be provided by the Sublessor, subject to certain terms contained in the Sublease. The Sublease contains customary provisions requiring us to pay our pro rata share of utilities and a portion of the operating expenses and certain taxes, assessments and fees of the Premises and provisions allowing the Sublessor to terminate the Sublease upon the termination of the lease with the Landlord or if we fail to remedy a breach of certain of our obligations within specified time periods. Additionally, we posted a security deposit of $0.9 million, which is reflected as restricted cash in non-current assets on our condensed balance sheets as of September 30, 2026 and December 31, 2025.

Funding Requirements

Based upon our current operating plan, we believe that our existing capital resources will enable us to fund our operating expenses and capital expenditure requirements through at least the next twelve months after the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates into and through clinical development, to develop, acquire or in-license other potential product candidates, pay our obligations and to fund operations for the foreseeable future.

We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, marketing and distribution arrangements, royalty monetizations, or other sources of financing. Adequate additional funding may not be available to us on acceptable

terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, and may cause us to delay, reduce the scope of or suspend one or more of our preclinical and clinical studies, research and development programs or commercialization efforts, and may necessitate us to delay, reduce or terminate planned activities in order to reduce costs. Due to the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.

To the extent we raise additional capital through new collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.

Cash Flows

The following table summarizes our cash flows during the periods indicated:

Cash Flows from Operating Activities

Cash used in operating activities for the nine months ended September 30, 2026 was $103.0 million. Our net loss of $108.5 million included non-cash amounts of $29.5 million for non-cash interest expense on our deferred royalty obligation, $5.7 million for stock-based compensation, $3.8 million for depreciation and amortization, $3.7 million for non-cash lease expense, and $1.2 million for the accretion of discount on marketable securities. Cash used in operating activities also reflected a net change in operating assets and liabilities of $36.3 million, due to an increase of $8.8 million in accounts receivable, a decrease of $6.9 million in accrued compensation expense primarily due to bonuses paid in 2026 in connection with the achievement of certain 2025 corporate goals, a decrease of $6.9 million in accrued expenses and other liabilities due primarily to a payment made to Vaxcyte partially offset by an increase in technology transfer costs, a decrease of $6.0 million in operating lease liabilities, a decrease of $4.7 million in accounts payable due to timing of payments, a decrease of $2.5 million in deferred revenue resulting from revenue recognized under the Astellas Agreement, and an increase of $0.5 million in prepaid expenses and other assets due primarily to an increase in clinical trials activities for STRO-004.

Cash used in operating activities for the nine months ended September 30, 2025 was $150.8 million. Our net loss of $144.3 million included non-cash amounts of $28.7 million for non-cash interest expense on our deferred royalty obligation, $12.4 million for stock-based compensation, $5.7 million for depreciation and amortization, $4.3 million for non-cash lease expense, and $2.9 million for the accretion of discount on marketable securities. Cash used in operating activities also reflected a net change in operating assets and liabilities of $55.1 million, due to a decrease of $69.6 million in deferred revenue resulting from Ipsen's strategic decision not to advance the STRO-003 program under its partnership with us and revenue recognized under the Astellas Agreement, a decrease of $5.5 million in operating lease liabilities, and a decrease of $3.0 million in accounts payable due to timing of payments, partially offset by a decrease of $14.4 million in prepaid expenses and other assets due to a decrease in clinical trials and CMO-related activities as a result of the deprioritization of STRO-002, a decrease of $4.7 million in accounts receivable due primarily to decreases in billing as a result of Ipsen's strategic decision not to advance the STRO-003 program and the completion of technology transfer, and an increase of $3.6 million in accrued expenses and other liabilities due primarily to increases in CMO restructuring costs as a result of the deprioritization of luvelta.

Cash Flows from Investing Activities

Cash used in investing activities of $11.1 million for the nine months ended September 30, 2026 was primarily related to purchases of marketable securities of $184.8 million, partially offset by maturities of marketable securities of $138.5 million, and sales of marketable securities of $35.4 million.

Cash provided by investing activities of $26.3 million for the nine months ended September 30, 2025 was primarily related to maturities of marketable securities of $251.3 million, and sales of marketable securities of $37.5 million, partially offset by purchases of marketable securities of $260.9 million, and purchases of property and equipment of $1.5 million, principally for laboratory equipment.

Cash Flows from Financing Activities

Cash provided by financing activities of $102.8 million for the nine months ended September 30, 2026 was primarily related to net proceeds from the sale of common stock in February 2026.

Cash provided by financing activities of $0.1 million for the nine months ended September 30, 2025 was primarily related to $0.4 million of net proceeds received from participants in our employee equity plans, partially offset by a $0.3 million tax payment related to the net share settlement of vested restricted stock units.

Contractual Obligations and Other Commitments

In addition to the contractual obligations and commitments as noted above and elsewhere in this Quarterly Report on Form 10-Q with regard to the leases, we enter into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice.

Critical Accounting Policies and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the year ended December 31, 2025.

Recent Accounting Pronouncements

See Note 2 to our financial statements included elsewhere in this report for more information.